Hepatitis

J&J offers government payer hep. C guarantee

The drugmaker is offering Scotland's NHS a money-back guarantee for Olysio patients.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Hep. C medication boosts J&J earnings

Hep. C medication boosts J&J earnings

By

Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

Harvoni's price is shaping the field

The regimen's anticipated average price of $80,000 is expected to determine how competitors stay competitive.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

By

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

Rate of Sovaldi non-adherence points to need for patient support

Rate of Sovaldi non-adherence points to need for patient support

By

A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.

Drug spend will continue to rise through 2023

Drug spend will continue to rise through 2023

By

The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.

Roche has no rights to Sovaldi, panel rules

Despite a collaboration with original Sovaldi owner Pharmasset in 2004, a panel ruled Roche has no rights to HCV treatment Sovaldi.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on horizon

By

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

J&J logs $19.5B in Q2 sales

J&J logs $19.5B in Q2 sales

By

Hepatitis C medication Olysio was a star, but the company cautions competition is coming.

Vertex to submit CF drug combo to FDA this year

Vertex to submit CF drug combo to FDA this year

By

Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.

BI calls it quits in hep. C

BI says there is no unmet need for faldaprevir.

FDA labels AbbVie hep C drug Breakthrough

The all-oral genotype 1 medication got the Breakthrough Therapy designation Friday.

Oregon seeks HCV Rx waiver

The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.

Medicare to cover some hep. C screening

Patients have to be high-risk or Baby Boomers for coverage.

Sovaldi Rx are being filled, despite payer angst

Sovaldi Rx are being filled, despite payer angst

By

Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.

Merck looks poised to challenge Gilead

Merck looks poised to challenge Gilead

By

Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.

Insurers struggle with Sovaldi angst

A report indicates that Sovaldi's high price may hurt health-insurance investors.

Merck adds heat to HCV competition

Merck adds heat to HCV competition

By

Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.

Merck adds heat to HCV competition

Merck adds heat to HCV competition

By

Phase-II data show reduced hepatitis-C RNA levels among HIV-positive patients, the drugmaker shared at a medical meeting. Boehringer also released co-infection data.

Sovaldi price worries states

Insurers and state agencies are wondering if and how they can cover the $84,000 hep. C drug.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

By

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Daclatasvir combo gets Breakthrough status

The FDA granted Breakthrough status to the daclatasvir + asunaprevir combo for hepatitis C patients with genotype 1b.

Gilead ponders Sovaldi price break

The drug maker is reportedly talking low rates for India's market.

Sovaldi launch trounces Incivek's

Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.

FDA greenlights Gilead's sofosbuvir

FDA greenlights Gilead's sofosbuvir

By

The drug is priced at $28,000 a month, before add-ons like ribavirin and (possibly) interferon.

Analyst: Don't underestimate AbbVie

Analyst: Don't underestimate AbbVie

By

Goldman Sachs's Jami Rubin says AbbVie's pipeline assets make it a stealth competitor.

J&J HCV drug OK'd; educational push planned

J&J HCV drug OK'd; educational push planned

By

Janssen's hepatitis C drug Olysio (simeprevir) offers modest benefit over standard of care, but resistance in a subgroup of patients could hinder broader uptake.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters